INV-144
The products in the INV-140 series (e.g. INV-141, INV-144, etc.) are the InVasc drugs at the most advanced stage of development. The INV-140 series is comprised of combinations of a generic ACE inhibitor with a specific antioxidant nutraceutical compound having unique properties that define the series. Our near term objective is to create value though the development of a combination product that has already demonstrated significant improvement (i.e. reduction) in proteinuria in hypertensive diabetics. In a Phase II, “proof-of-concept” (POC) investigator initiated clinical trial, The QUALITY Study, sponsored by InVasc to evaluate an Antihypertensive inhibitor-nutraceutical combination, statistical significance was achieved for the primary endpoint of proteinuria and multiple secondary endpoints. An IND for INV-144 and will be filed as a 505(b)2 submission near the end of 2010.
There are approximately 36 million patients in the U.S. with chronic kidney disease. The data from the QUALITY study suggests that INV-144 can slow the progress of the disease. At Stage V kidney disease patients must undergo dialysis or transplant, both life altering and costly alternatives.
The combinations in the INV-144 Series are protected by pending patents, which we believe will provide appropriate exclusivity in both the U.S. and Europe.
Proof of Concept demonstrated in a Phase II Clinical
